Huons Co., Ltd. (KOSDAQ:243070)

Market Cap	295.37B -6.0%
Revenue (ttm)	620.77B +5.2%
Net Income	42.66B +44.8%
EPS	3,600.00 +51.6%
Shares Out	11.65M
PE Ratio	7.04
Forward PE	n/a
Dividend	920.00 (3.63%)
Ex-Dividend Date	Apr 2, 2026

Volume	17,229
Average Volume	14,368
Open	25,450
Previous Close	25,350
Day's Range	25,400 - 26,050
52-Week Range	23,100 - 32,200
Beta	0.15
RSI	48.79
Earnings Date	May 15, 2026

About Huons

Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other chemotherapeutic products; and injection products, such as anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1965
• Employees: 912
• Stock Exchange: KOSDAQ
• Ticker Symbol: 243070

Financial Performance

In 2025, Huons's revenue was 620.77 billion, an increase of 5.17% compared to the previous year's 590.23 billion. Earnings were 42.66 billion, an increase of 44.84%.